Brief: Clarity Pharmaceuticals Receives Confirmation From US Food And Drug Administration
07/02/2022 01:36
Feb 7 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* RECEIVED CONFIRMATION FROM US FOOD AND DRUG ADMINISTRATION
THAT
DIAGNOSTIC 64 CU SAR-BISPSMA TRIAL MAY PROCEED
Source text for Eikon: ID:nASXbHwg73
Further company coverage: CU6.AX
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial